Smruthi Organics Ltd
BSE:540686
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1.8), the stock would be worth ₹131.75 (15% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.6 | ₹114.85 |
0%
|
| 3-Year Average | 1.8 | ₹131.75 |
+15%
|
| 5-Year Average | 2.2 | ₹162.69 |
+42%
|
| Industry Average | 3.3 | ₹243.03 |
+112%
|
| Country Average | 2.3 | ₹165.42 |
+44%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Smruthi Organics Ltd
BSE:540686
|
1.3B INR | 1.6 | 28.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
910.2B USD | 9.4 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 3.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 2.6 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 1 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.2B USD | 2 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.3 |
| Median | 2.3 |
| 70th Percentile | 4.2 |
| Max | 4 185.7 |
Other Multiples
Smruthi Organics Ltd
Glance View
Smruthi Organics Ltd. engages in the manufacture and sale of bulk drugs and drug intermediates. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2017-08-29. The Company’s operating segments include Formulation. The firm's products include AMLODIPINE BESILATE, AMISULPRIDE, CARBIDOPA, CIPROFLOXACIN, DILOXANIDE FUROATE, FENOFIBRATE, METFORMIN HYDROCHLORIDE, NORFLOXACIN, PEFLOXACIN, TELMISARTAN, AMLODIPINE BASE and PHTHALOYL AMLODIPINE. The firm has 2 manufacturing facilities in Solapur, Maharashtra. with a combined reactor capacity of over 320 kiloliters. The firm manufactures API from kilo to metric ton scale. The firm serves pharmaceutical companies in India and across the globe. The firm caters to both domestic and international markets.
